Research finds change in the outlook of people with type 2 diabetes and heart dise...
The outlook for individuals with type 2 diabetes and coronary artery disease is not as grim as originally believed, according to new Saint Louis University research published in Circulation...
News-Medical-Net,
Wed Dec 02 20:45:24 PST 2009
• Found on Yahoo! News
Amgen to present updated data on Nplate at the 2009 ASH meeting
Amgen Inc. today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Add...
News-Medical-Net,
Tue Dec 01 01:30:24 PST 2009
• Found on Yahoo! News
Topix.net
360,000 news channels, from Autos to your ZIP code.
• Found on Topix News
Commercial Insight: Antidiabetics In Australia - Reimbursement Status Shapes Novel...
The Australian antidiabetics market is expected to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patie...
OfficialWire,
Sat Nov 28 00:56:53 PST 2009
• Found on Yahoo! News
European Commission approves MICARDIS medication for CV protection
MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the ...
News-Medical-Net,
Fri Nov 27 01:55:03 PST 2009
• Found on Yahoo! News
Commercial Insight: Antidiabetics In Australia - Reimbursement Status Shapes Novel...
The Australian antidiabetics market is expected to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patie...
OfficialWire,
Sat Nov 28 00:56:35 PST 2009
• Found on Yahoo! News